Paper Details

  1. Home
  2. Paper Details

New Insights into the Use of Empagliflozin-A Comprehensive Review.

Author: ForyckaJoanna, FranczykBeata, HajdysJoanna, KrzemińskaJulia, MłynarskaEwelina, RyszJacek, WilczopolskiPiotr, WronkaMagdalena

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Empagliflozin, an SGLT2 inhibitor, has proven effective in improving glycemic control and reducing the risk of cardiovascular and renal events in patients with type 2 diabetes mellitus (T2DM). While generally well-tolerated, empagliflozin may cause side effects, including symptomatic hypotension, genital fungal infections, and urinary tract infections. Its use is contraindicated in patients with severe hypersensitivity or a glomerular filtration rate (GFR) < 30 mL/min/1.73 m2.
Paper Details　
Original Abstract of the Article :
Empagliflozin is a relatively new drug that, as an inhibitor of the sodium−glucose cotransporter 2 (SGLT2), causes increased urinary glucose excretion and thus contributes to improved glycemic control, better glucose metabolism, reduced glucotoxicity and insulin resistance. Although its original use...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775057/

データ提供：米国国立医学図書館（NLM）

Empagliflozin: A Multifaceted Approach to Diabetes and Beyond

This research delves into the world of diabetes management, focusing on empagliflozin, a relatively new drug that works by increasing urinary glucose excretion, thereby improving glycemic control. Empagliflozin is like a skilled desert guide, leading individuals with type 2 diabetes towards a healthier path by helping regulate their blood sugar levels. This study examines the multifaceted benefits of empagliflozin, exploring its potential for treating not only diabetes but also other health conditions, such as heart failure and kidney disease.

The researchers highlight the remarkable benefits of empagliflozin, which extend beyond blood sugar control. They found that this medication also demonstrates nephroprotective effects, reducing the risk of kidney failure and cardiovascular events, including death from cardiovascular causes. It’s like a multi-faceted oasis in the desert, offering not only water but also shade and sustenance to travelers battling the harsh environment.

Empagliflozin: A Promising New Frontier

This research presents a compelling case for empagliflozin as a promising new therapy for diabetes and other related conditions. It highlights the potential of this medication to improve overall health and quality of life for individuals facing these challenges.

Navigating the Sands of Diabetes Management

This research underscores the importance of seeking appropriate medical care and engaging in open dialogue with healthcare providers to manage diabetes effectively. It reminds us that there are options available to help navigate the complexities of diabetes management and improve our overall well-being.

Dr. Camel’s Conclusion

This comprehensive review of empagliflozin highlights its multifaceted benefits for treating diabetes and other related conditions. It demonstrates the potential of this medication to improve glycemic control, protect against kidney failure, and reduce the risk of cardiovascular events. This research is a testament to the ongoing progress in the field of diabetes management, offering new hope for individuals seeking effective treatments and a healthier future.
Date :
  1. Date Completed n.d.
  2. Date Revised 2023-03-08
Further Info :

Pubmed ID

36552050

DOI: Digital Object Identifier

PMC9775057

Related Literature

Article Analysis
・Side Effects of empagliflozin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.